scPharmaceuticals (SCPH) to Release Quarterly Earnings on Wednesday

scPharmaceuticals (NASDAQ:SCPH) will likely be announcing its Q3 2025 results before the market opens on Wednesday, November 12th. Analysts expect the company to announce earnings of ($0.25) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Wednesday, November 12, 2025 at 4:30 PM ET.

scPharmaceuticals (NASDAQ:SCPH) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.04). scPharmaceuticals had a negative return on equity of 1,647.86% and a negative net margin of 183.55%.The firm had revenue of $16.04 million during the quarter, compared to analyst estimates of $15.41 million. On average, analysts expect scPharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

scPharmaceuticals Price Performance

Shares of SCPH stock opened at $5.67 on Wednesday. scPharmaceuticals has a 12 month low of $1.94 and a 12 month high of $6.28. The firm has a market capitalization of $302.20 million, a P/E ratio of -3.13 and a beta of 0.31. The company’s fifty day moving average price is $5.63 and its two-hundred day moving average price is $4.56.

Analyst Upgrades and Downgrades

Several research firms recently commented on SCPH. HC Wainwright cut scPharmaceuticals from a “strong-buy” rating to a “hold” rating and set a $5.35 price target on the stock. in a research note on Friday, August 29th. Craig Hallum cut shares of scPharmaceuticals from a “buy” rating to a “hold” rating and set a $6.00 price target on the stock. in a report on Monday, August 25th. Maxim Group cut shares of scPharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, August 25th. Weiss Ratings restated a “sell (d-)” rating on shares of scPharmaceuticals in a research note on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of scPharmaceuticals to a “hold” rating in a research note on Saturday, October 11th. Three research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Reduce” and a consensus price target of $7.78.

Institutional Trading of scPharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the business. Rhumbline Advisers raised its holdings in shares of scPharmaceuticals by 5.8% during the second quarter. Rhumbline Advisers now owns 54,500 shares of the company’s stock worth $208,000 after purchasing an additional 3,001 shares during the period. Captrust Financial Advisors raised its stake in scPharmaceuticals by 9.0% during the second quarter. Captrust Financial Advisors now owns 43,746 shares of the company’s stock worth $167,000 after acquiring an additional 3,621 shares during the period. Comerica Bank raised its stake in scPharmaceuticals by 22.1% during the first quarter. Comerica Bank now owns 38,662 shares of the company’s stock worth $102,000 after acquiring an additional 7,000 shares during the period. XTX Topco Ltd acquired a new stake in scPharmaceuticals during the second quarter worth about $121,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in scPharmaceuticals during the first quarter worth about $76,000. 89.52% of the stock is owned by institutional investors and hedge funds.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.